This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Panbela Therapeutics’s 8K filing here.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Featured Articles
- Five stocks we like better than Panbela Therapeutics
- Ride Out The Recession With These Dividend Kings
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Using the MarketBeat Dividend Tax Calculator
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
